02.03.14
Zoll Medical Corporation's Japanese subsidiary, Asahi Kasei Zoll Medical (AZM), has received Shonin approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its X Series Monitor/Defibrillator.
Created in August 2012 to pursue the regulatory approval, sale, and marketing of Zoll products in Japan, AZM will begin marketing and selling the X Series in the spring. Designed primarily for EMS operations and critical care transport, the X Series is about half the size and half the weight of competitive full-featured monitor/defibrillators, yet more powerful and rugged.
Weighing less than 12 pounds (six kilograms), the X Series is compact, combining the clinically therapeutic capabilities of Zoll defibrillation, pacing, and cardiopulmonary resuscitation (CPR) assistance with advanced monitoring parameters.
Key among the X Series’ features is the ability to help improve CPR quality to keep oxygen-rich blood flowing. Zoll’s proprietary See-Thru CPR minimizes the duration of pauses in CPR to enable rescuers to see the underlying rhythm. Zoll’s Real CPR Help provides real-time CPR feedback, and a built-in sensor measures the depth, rate, and effectiveness of chest compressions.
The X Series also allows first responders assess the patient’s needs quickly and wirelessly transmit critical information to a receiving hospital so clinicians are prepared when the ambulance arrives. Wireless transmission allows the EMS crew and hospital staff to work as a team and start treating the patient without delay.
“We are very excited to begin commercialization of the X Series in Japan and to offer technologies and devices for acute critical care to this high-growth market,” said Richard A. Packer, CEO of Zoll.
The X Series provides electrocardiography monitoring, invasive and non-invasive blood pressure, pulse oximetry (including SpO2, CO, etc.), end-tidal carbon dioxide concentration (EtCO2), body temperature, and respiratory rate.
Other Zoll products that received Shonin approval in Japan:
The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 29,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries.
Created in August 2012 to pursue the regulatory approval, sale, and marketing of Zoll products in Japan, AZM will begin marketing and selling the X Series in the spring. Designed primarily for EMS operations and critical care transport, the X Series is about half the size and half the weight of competitive full-featured monitor/defibrillators, yet more powerful and rugged.
Weighing less than 12 pounds (six kilograms), the X Series is compact, combining the clinically therapeutic capabilities of Zoll defibrillation, pacing, and cardiopulmonary resuscitation (CPR) assistance with advanced monitoring parameters.
Key among the X Series’ features is the ability to help improve CPR quality to keep oxygen-rich blood flowing. Zoll’s proprietary See-Thru CPR minimizes the duration of pauses in CPR to enable rescuers to see the underlying rhythm. Zoll’s Real CPR Help provides real-time CPR feedback, and a built-in sensor measures the depth, rate, and effectiveness of chest compressions.
The X Series also allows first responders assess the patient’s needs quickly and wirelessly transmit critical information to a receiving hospital so clinicians are prepared when the ambulance arrives. Wireless transmission allows the EMS crew and hospital staff to work as a team and start treating the patient without delay.
“We are very excited to begin commercialization of the X Series in Japan and to offer technologies and devices for acute critical care to this high-growth market,” said Richard A. Packer, CEO of Zoll.
The X Series provides electrocardiography monitoring, invasive and non-invasive blood pressure, pulse oximetry (including SpO2, CO, etc.), end-tidal carbon dioxide concentration (EtCO2), body temperature, and respiratory rate.
Other Zoll products that received Shonin approval in Japan:
- --- The AED Plus, an automated external defibrillator (AED) that incorporates Zoll’s real-time CPR feedback technology, Real CPR Help. The AED Plus is the only AED with CPR feedback capability available in the Japanese market.
- --- The AutoPulse Non-Invasive Cardiac Support Pump, an automated, portable chest compression device. It is the only mechanical CPR system to have shown improved survival in comparative clinical trials. The AutoPulse more than tripled survival compared to typical CPR during witnessed shockable arrests.
- --- Zoll’s Intravascular Temperature Management (IVTM) system, which enables healthcare providers to rapidly, safely, and effectively manage the core body temperature of critically ill or surgical patients. In Japan, IVTM only is approved for patients with high fever.
The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 29,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries.